Adherence to Iron Chelation Therapy with Deferasirox Formulations among Patients with Sickle Cell Disease and ß-thalassemia.

Oyedeji, Charity I; Crawford, Regina D; Shah, Nirmish

Oyedeji, Charity I; Crawford, Regina D; Shah, Nirmish.

Afiliación

Oyedeji CI; Division of Hematology, Duke University School of Medicine Durham, NC, USA. Electronic address: Charity.Oyedeji@duke.edu.
Crawford RD; Division of Hematology, Duke University School of Medicine Durham, NC, USA; Department of Medicine, Duke Comprehensive Sickle Cell Center, Duke University School of Medicine Durham, NC, USA.
Shah N; Division of Hematology, Duke University School of Medicine Durham, NC, USA; Department of Medicine, Duke Comprehensive Sickle Cell Center, Duke University School of Medicine Durham, NC, USA; Division of Pediatric Hematology/Oncology, Duke University School of Medicine Durham, NC, USA.

J Natl Med Assoc ; 113(2): 170-176, 2021 Apr.

Article en En | MEDLINE | ID: mdl-32892996

Asunto(s)

Anemia de Células Falciformes; Talasemia beta; Terapia por Quelación; Deferasirox; Humanos; Hierro; Quelantes del Hierro/uso terapéutico; Estudios Retrospectivos; Talasemia beta/tratamiento farmacológico

Palabras clave

Deferasirox; Iron chelation therapy; Iron overload; Sickle cell disease; Thalassemia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Talasemia beta / Anemia de Células Falciformes Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Natl Med Assoc Año: 2021 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google